Table 6. Multivariate Analysis of Progression-Free Survival.

Variable	Ad, EGFR mt (-)	P	NSCLC, EGFR mt (+)	P	SQ	P
	HR (95% CI)		HR (95% CI)		HR (95% CI)
Age, years
< 70	1 (Reference)		1 (Reference)		1 (Reference)
≥ 70	1.09 (0.77 - 1.53)	0.62	1.25 (0.82 - 1.90)	0.30	1.13 (0.71 - 1.80)	0.61
Smoking history
Non-smoker	1 (Reference)		1 (Reference)		1 (Reference)
Smoker	1.01 (0.65 - 1.58)	0.96	1.08 (0.72 - 1.60)	0.72	1.22 (0.53 - 2.82)	0.64
No. of metastatic sites
< 2	1 (Reference)		1 (Reference)		1 (Reference)
≥ 2	0.99 (0.71 - 1.38)	0.94	1.52 (0.94 - 2.45)	0.09	1.10 (0.66 - 1.85)	0.72
ECOG-PS
0 or 1	1 (Reference)		1 (Reference)		1 (Reference)
≥ 2	1.90 (1.26 - 2.86)	< 0.01	1.48 (0.86 - 2.55)	0.16	1.82 (1.04 - 3.18)	0.04
Bevacizumab-containing
Yes	1 (Reference)
No	1.40 (0.93 - 2.12)	0.11
PTX or nab-PTX-containing
Yes					1 (Reference)
No					1.53 (0.95 - 2.45)	0.08
EGFR-TKI line
First			1 (Reference)
Second or later			0.76 (0.47 - 1.21)	0.24
Albumin level, g/dL
≥ 3.5	1 (Reference)		1 (Reference)		1 (Reference)
< 3.5	1.15 (0.79 - 1.67)	0.48	0.80 (0.46 - 1.37)	0.41	0.90 (0.57 - 1.44)	0.67
LIPI
Good	1 (Reference)		1 (Reference)		1 (Reference)
Intermediate	1.00 (0.70 - 1.43)	1.00	1.57 (1.01 - 2.44)	0.04	1.08 (0.67 - 1.73)	0.75
Poor	1.35 (0.78 - 2.34)	0.29	2.63 (1.14 - 6.07)	0.02	2.00 (0.94 - 4.22)	0.07

Ad: adenocarcinoma; CI: confidence interval; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitor; HR: hazard ratio; LIPI: lung immune prognostic index; nab-PTX: nanoparticle albumin-bound paclitaxel; NSCLC: non-small cell carcinoma; PTX: paclitaxel; SQ: squamous cell carcinoma.